Extended resection for potentially operable patients with stage III non–small cell lung cancer after induction treatment

Furrer, Katarzyna; Weder, Walter; Eboulet, Eric Innocents; Betticher, Daniel; Pless, Miklos; Stupp, Roger; Krueger, Thorsten; Perentes, Jean Yannis; Schmid, Ralph A.; Lardinois, Didier; Furrer, Markus; Früh, Martin; Peters, Solange; Curioni-Fontecedro, Alessandra; Stahel, Rolf A.; Rothschild, Sacha I.; Hayoz, Stefanie; Opitz, Isabelle

doi:10.1016/j.jtcvs.2022.03.034

Cited by 10 publications

(13 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Whole body MRI had the advantage to reduce the time to staging completion and costs 17 with limitations in lymph node evaluation. Indeed whole body MRI had a 65% agreement for the N stage compared with 75% for the standard pathway, a significant difference of 10% (3)(4)(5)(6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18).…”

Section: Resectability Assessmentmentioning

confidence: 96%

“…In expert centers, surgery provides acceptable results (Table 1). In a pooled analysis of three prospective multicenter trials from the Swiss Group of Clinical Cancer Research, we set out to evaluate the oncologic efficacy of those particular patients 7 …”

Section: Patients' Assessmentmentioning

confidence: 99%

“…In a pooled analysis of three prospective multicenter trials from the Swiss Group of Clinical Cancer Research, we set out to evaluate the oncologic efficacy of those particular patients. 7 A total of 197 patients had T3/T4 NSCLC amongst 368 patients with Stage III NSCLC. A total of 38 out of 197 patients were not resected for technical (81%) or medical (19%) reasons.…”

Section: Extended Resectionsmentioning

confidence: 99%

“…A crucial question during these meetings is determining whether stage III disease is resectable and if better local tumor control can be achieved with surgery and/or radiotherapy and in which sequence and combination the different modalities should be applied. Main prognostic factors have been shown to be the N status of the patient and R0 resection 6,7 …”

Section: Introductionmentioning

confidence: 99%

“…3 A crucial question during these meetings is determining whether stage III disease is resectable and if better local tumor control can be achieved with surgery and/or radiotherapy and in which sequence and combination the different modalities should be applied. Main prognostic factors have been shown to be the N status of the patient and R0 resection 6,7 The aim of this review is to highlight the oncologic efficacy of extended resections for stage III NSCLC and share surgical challenges presented by those locoregional advanced tumors. Interesting perspectives offered by new innovative molecules, represented by targeted therapy or immune checkpoint inhibitors will also be discussed.…”

mentioning

confidence: 99%

See 4 more Smart Citations

The oncologic efficacy of extended resections for lung cancer

Etienne

Kalt

Park

et al. 2023

Journal of Surgical Oncology

Self Cite

View full text Add to dashboard Cite

Extended lung resections for T3-T4 non-small-cell lung cancer remain challenging.Multimodal management is mandatory in multidisciplinary tumor boards, and here the determination of resectability is key. Long-term oncologic efficacy depends mostly on complete resection (R0) and the extent of N2 disease. The development of novel innovative treatments (targeted therapy and immune checkpoint inhibitors) sets interesting perspectives to reinforce current therapeutic options in the induction and adjuvant setting.

show abstract

Section: Resectability Assessmentmentioning

confidence: 96%

Section: Patients' Assessmentmentioning

confidence: 99%

Section: Extended Resectionsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations

The oncologic efficacy of extended resections for lung cancer

Etienne

Kalt

Park

et al. 2023

Journal of Surgical Oncology

Self Cite

View full text Add to dashboard Cite

show abstract

Stage 3 N2 Lung Cancer: A Multidisciplinary Therapeutic Conundrum

Carter,

Apte,

Shukla

et al. 2024

Curr Oncol Rep

View full text Add to dashboard Cite

Purpose of Review The treatment of stage III N2 non-small cell lung cancer (NSCLC) remains debated. There is an absence of a universally agreed definition of resectability for this heterogeneous group and a lack of trial data. Recent Findings We reviewed and compared current international guidelines and evidence surrounding management of stage III N2 NSCLC. The Irish and Australian guidelines advise subcategorising N2 disease into N2a (may be resectable) and N2b (never resectable). On the contrary, American and British guidelines avoid subcategorising N2 disease, emphasising importance of local MDT decisions. It is suggested that evidence for resection of stage III tumours is relatively weak, but that stage IIIA should generally be considered for resection, and stage IIIB is not recommended for resection. For resectable disease, surgery may be combined with neoadjuvant chemoimmunotherapy, or adjuvant chemotherapy followed by immunotherapy and radiotherapy in selected patients. Summary There is some evidence that technically resectable disease can be treated solely with radiotherapy with similar outcomes to resection. In the event of unresectable disease, chemoradiotherapy has been the traditional management option. However, recent studies with chemoradiotherapy alongside immunotherapy appear promising. There are many factors that influence the treatment pathway offered to patients with stage III N2 NSCLC, including patient factors, team expertise, and local resources. Therefore, the role of MDTs in defining resectability and formulating an individualised treatment plan is crucial.

show abstract

Surgery patterns and survival of T4N2 non-small cell lung cancer – A population-based analysis

Zhang,

Chen

et al. 2024

Clinical Surgical Oncology

View full text Add to dashboard Cite

Extended resection for potentially operable patients with stage III non–small cell lung cancer after induction treatment

Cited by 10 publications

References 32 publications

The oncologic efficacy of extended resections for lung cancer

The oncologic efficacy of extended resections for lung cancer

Stage 3 N2 Lung Cancer: A Multidisciplinary Therapeutic Conundrum

Surgery patterns and survival of T4N2 non-small cell lung cancer – A population-based analysis

Contact Info

Product

Resources

About